Otsuka Pharmaceutical Co., Ltd.
Favorable judgment on lawsuit for revocation of trial decision on patent right held in relation to equol-containing foods
Otsuka Pharmaceutical Co., Ltd. hereby announces that a judgment was rendered on December 16, 2021 on an action seeking the revocation of a trial decision concerning the company's patent right for equol-containing foods (Patent Registration No. 6275313; Title of Invention: Equol-containing extract and method for producing the same, equol extraction method, and food containing equol; hereinafter the "Patent Right"). The judgment accepts the company's arguments and maintains the validity of the Patent Right.
Otsuka will continue to vigorously defend and protect its inventions in relevant fields of technology, and provide safe and high-quality products and information to support people's health based on scientific evidence.
Otsuka Pharmaceutical Foods Containing Equol
EQUELLE was launched in April of 2014 as the supplement containing equol, made by fermenting a soy isoflavone component with lactic acid bacterium. The product was initially sold as a basic supplement to support the health and beauty of women aged 40 and over. The EQUELLE product line has since been expanded by the addition of equol-containing Equelle Gelée and tocoelle, products developed to support women during different life-stage transitions.
- * Court
- Intellectual Property High Court
- Case number
- 2020 (Gyo-Ke) #10150
- Case name
- Appeal proceedings to decision of Japan Patent Office
- Daicel Corporation
- Additional plaintiff
- Advanced Medical Care Inc.
- Otsuka Pharmaceutical Co., Ltd.